|Born||March 17, 1983|
Brooklyn, New York, U.S.
|Alma mater||Baruch College|
|Occupation||Co-founder of MSMB Capital Management, Co-founder and former CEO of Retrophin|
Founder and former CEO of Turing Pharmaceuticals.
|Known for||Turing Pharmaceuticals; Retrophin|
|Net worth||US$70 million (June 2017)|
|Criminal charge(s)||Securities fraud|
Martin Shkreli (//, born March 17, 1983) is an American businessman, former hedge fund manager and convicted fraudster. He is the co-founder of the hedge funds Elea Capital, MSMB Capital Management, MSMB Healthcare, co-founder and former chief executive officer (CEO) of the biotechnology firm Retrophin, and founder and former CEO of Turing Pharmaceuticals.
Controversy[change | change source]
In September 2015, Shkreli received widespread criticism when Turing got the manufacturing license for the antiparasitic drug Daraprim and raised its price by a factor of 56 (from $13.50 to $750 per pill), leading him to be referred to as "the most hated man in America" and "pharma bro".
Arrest and conviction[change | change source]
In December 2015, Shkreli was arrested by the FBI after being indicted on federal charges of securities fraud. He subsequently as CEO of Turing Pharmaceuticals and was replaced by the company's board chairman, Ron Tilles. Shkreli was convicted of two counts of securities fraud and one count of conspiring to commit securities fraud in August 2017. In May 2022, he was released from prison to a halfway house.
References[change | change source]
- Matthews, Christopher M.; Copeland, Rob; O'Brien, Rebecca Davis. "Martin Shkreli, Pharma Executive, Arrested on Fraud Charges". The Wall Street Journal. ISSN 0099-9660. Retrieved December 17, 2015.
- Creswell, Julie; Clifford, Stephanie; Pollack, Andrew; Goldstein, Matthew; Chen, David (December 17, 2015). "Drug C.E.O. Martin Shkreli Arrested on Fraud Charges". The New York Times. pp. A1, B6. ISSN 0362-4331. Archived from the original on February 5, 2016.
Mr. Shkreli, a pharmaceutical industry entrepreneur...
- Matyszczyk, Chris (February 4, 2016). "Icons of Entrepreneurship: Why Martin Shkreli Speaks For Many Entrepreneurs". Inc.Com. Inc. (magazine). Retrieved September 24, 2016.
- Rockoff, Jonathan D. (December 17, 2015). "Martin Shkreli: From Biotech Entrepreneur to Accused Criminal". wsj.com. Wall Street Journal. Retrieved September 24, 2016.
- Chohan, Usman W. (January 8, 2015). "Martin Shkreli and the outrage of inequality". The Conversation. Retrieved October 26, 2016.
- Mangan, Dan (2017-06-30). "'Pharma Bro' Martin Shkreli 'wanted to be Stevie Cohen,' investor says". CNBC. Retrieved 2017-07-01.
- Shina, Lucinda (September 23, 2015). "Here's What 'The Most Hated Man in America' Thinks About Donald Trump". New York, NY: Fortune.
- "Martin Shkreli - 'American's most hated man' - auctioning off chance to hit him in the face". The Telegraph. Retrieved 2017-02-16.
- "Martin Shkreli quits Turing Pharmaceuticals after arrest". BBC News. December 18, 2015.
- Pollack, Andrew (December 19, 2015). "Martin Shkreli Resigns From Turing Pharmaceuticals". The New York Times.
- "Turing Pharmaceuticals AG Announces Appointment of Ron Tilles as Interim CEO". Turing Pharmaceuticals.
- Merle, Renae (August 4, 2017). "Martin Shkreli is found guilty of securities fraud". The Washington Post.
- "'Pharma Bro' Martin Shkreli released from prison early". the Guardian. 2022-05-18. Retrieved 2022-07-02.
Other websites[change | change source]
Media related to Martin Shkreli at Wikimedia Commons